New Zealand Gazette – 1992 – No. 95

Page 2173

✨ Health and Revenue Notices



25 JUNE NEW ZEALAND GAZETTE 2173

instruct the Crown Solicitor in the area health district to represent the board in the proceedings.

  1. Where, in the view of the area health board, offences against any of the Acts or regulations referred to in Part A of the Schedule to this delegation (other than the Food Act 1981, the Food Hygiene Regulations 1974, the Food Regulations 1984, and the Dietary Supplementary Regulations 1985) have occurred, the Board shall inform the Department of Health, to enable prosecution of the alleged offender at the instance of an officer of the department to be considered.

Dated at Wellington this 19th day of June 1992.

I. MILLER, Acting Director-General of Health.

go5745

Medicines Act 1981

Consent to the Distribution of a New Related Product

Pursuant to section 96 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new related product set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Salicylic Acid 0.5% w/v
Triclosan 0.2% w/v Medicated pads SmithKline Beecham Health Care, Saint Helens, Merseyside, England Oxy Duo Pads

Dated this 17th day of June 1992.

I. MILLER, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on the 5th day June 1991.

go5754

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Cytarabine 100 mg/5 ml, 1000 mg/10 ml, 2000 mg/20 ml Solution for injection Delta West Pty Limited, Bentley, Western Australia Cytarabine injection
Apraclonidine hydrochloride 1.15% w/v Ophthalmic solution Automated Liquid Packaging Corporation, Woodstock, Illinois, United States of America Iopidine
Terbinafine as hydrochloride 1% Cream Sandoz Pharma Limited, Basle, Switzerland Lamisil
Terbinafine as hydrochloride 125 mg, 250 mg Tablets Sandoz Pharma Limited, Basle, Switzerland Lamisil
Dipyridamole 150 mg Tablets Euderma Srl, Cerasolo di Coriano, Italy and Valpharma SA, Serravalle, Republic of San Marino Pytazen SR
Timololo maleate 10 mg Tablet Glaxo New Zealand Limited, Palmerston North Timolol
Sertraline (as the hydrochloride) 50 mg, 100 mg Tablets Pfizer Limited, Sandwich, Kent, England Zoloft
Bovine dermal glutaraldehyde cross linked collagen 35 mg/cc Injectable gel Collagen Corporation, Palo Alto, California, United States of America Contigen Bard
Formoterol fumarate 12 µg/puff Metered dose inhaler 3M Health Care, Loughborough, Leicestershire, England Foradil

Dated this 17th day of June 1992.

I. MILLER, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on the 5th day June 1991.

go5755

Inland Revenue

Income Tax Act 1976

Determination G17B: Deferred Property Settlements Denominated in New Zealand Currency

This determination may be cited as “Determination G17B: Deferred Property Settlements Denominated in New Zealand Currency”.

  1. Explanation—(which does not form part of the determination)

(1) This determination rescinds and replaces Determination G17A: Discounted value of Amounts Payable in Relation to Deferred Property Settlements Denominated in New Zealand Currency.

Currency made by the Commissioner on 9 February 1990. This determination differs from Determination G17A:

(a) By expanding the scope of the determination to ensure the acquisition price, for the purposes of the base price adjustment, must be determined in all circumstances;

(b) Making it clear that if all the amounts Payable and the dates on which those amounts are Payable are known at the first balance date after the Transfer Date the yield to maturity method must be applied to calculate income derived or expenditure incurred during the term of the Deferred Property Settlement;

(c) Providing a method of calculating income derived or expenditure incurred during the term of a Deferred Property Settlement where the amounts Payable or the dates on which those amounts are Payable are not known



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa — PDF NZ Gazette 1992, No 95


NZLII — PDF NZ Gazette 1992, No 95




✨ LLM interpretation of page content

🏥 Delegation of Health Functions to Area Health Boards (continued from previous page)

🏥 Health & Social Welfare
19 June 1992
Health Functions, Delegation, Area Health Boards, Prosecution
  • I. MILLER, Acting Director-General of Health

🏥 Consent to Distribution of New Related Product

🏥 Health & Social Welfare
17 June 1992
Medicines, Distribution, Salicylic Acid, Triclosan, Oxy Duo Pads
  • I. MILLER, Acting Director-General of Health

🏥 Consent to Distribution of New Medicines

🏥 Health & Social Welfare
17 June 1992
Medicines, Distribution, Cytarabine, Apraclonidine, Terbinafine, Dipyridamole, Timolol, Sertraline, Collagen, Formoterol
  • I. MILLER, Acting Director-General of Health

💰 Determination G17B: Deferred Property Settlements Denominated in New Zealand Currency

💰 Finance & Revenue
Income Tax, Property Settlements, Deferred Payments, Currency